Author

M. Karim

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

S. Einav· 5 shared A. Narayanan· 3 shared N. Bhalla· 3 shared S. Saul· 3 shared B. A. Pinsky· 2 shared J. Jin· 2 shared L. Ghita· 2 shared S. De Jonghe· 2 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

S. Einav

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Back-pocket optimization of 2-aminopyrimidine-based macrocycles leads to potent dual EPHA2/GAK kinase inhibitors with antiviral activity

J. Gerninghaus, R. Zhubi, A. Kraemer, M. Karim, D. H. N. Tran, A. C. Joerger, C. Schreiber, L. M. Berger, B. T. Berger, T. A. L. Ehret, L. Elson, C. Lenz, K. Saxena, S. Mueller, S. Einav, , T. Hanke

The paper optimizes a 2-aminopyrimidine-based macrocycle to create a dual EPHA2/GAK kinase inhibitor with antiviral activity against dengue virus.

bioRxiv · Feb 18, 2024 · PreprintBiochemistry

Design of SARS-CoV-2 protease inhibitors with improved affinity and reduced sensitivity to mutations

M. Westberg, Y. Su, X. Zou, P. Huang, A. Rustagi, J. Garhyan, P. B. Patel, D. Fernandez, Y. Wu, L. Ning, A. Beck, M. Karim, C. Hao, P. Saenkham-Huntsinger, V. Tat, , M. Z. Lin

This study designs a SARS-CoV-2 protease inhibitor with improved affinity and reduced mutation sensitivity compared to existing drugs.

bioRxiv · Jul 19, 2023 · PreprintMicrobiology

Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for therapy

M. Karim, S. Saul, L. Ghita, M. K. Sahoo, C. Ye, N. Bhalla, J. Jin, J.-G. Park, B. Martinez-Gualda, M. Patrick East, G. L. Johnson, B. A. Pinsky, L. Martinez-Sobrido, C. R. M. Asquith, A. Narayanan, , S. Einav

This study shows that Numb-associated kinases are essential for SARS-CoV-2 infection and that inhibiting them can suppress viral infection in human lung cells.

bioRxiv · Mar 18, 2022 · PreprintMicrobiology

Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen

S. Saul, M. Karim, P.-T. Huang, L. Ghita, W. Chiu, S. Kumar, N. Bhalla, P. Leyssen, C. A. Cohen, K. E. Huie, C. Tindle, M. Sibai, B. A. Pinsky, S. Das, P. Ghosh, , S. Einav

This study identifies lapatinib, an ErbB inhibitor, as a broad-spectrum antiviral that suppresses SARS-CoV-2 and VEEV replication, inflammation, and lung injury through ErbB-mediated mechanisms.

bioRxiv · May 15, 2021Microbiology

The transcriptional landscape of Venezuelan equine encephalitis virus (TC-83) infection

Z. Yao, F. Zanini, S. Kumar, M. Karim, S. Saul, N. Bhalla, N. Panpradist, A. Muniz, A. Narayanan, S. R. Quake, S. Einav

This study uses single-cell RNA sequencing to analyze the host and viral RNA dynamics during VEEV infection, identifying superproducer cells and candidate antiviral targets.

bioRxiv · Feb 18, 2020Microbiology